Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xiaomeng Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3288-212X; OpenAlex author ID A5100749515. Sources: OpenAlex.

Their work

Papers
11 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. TGF-β-Targeting Platinum(IV) Prodrugs Remodel Tumor Microenvironment of Pancreatic Cancer via Antifibrotic and Immunomodulatory Effects. First author DOI 10.1021/acs.jmedchem.6c01687↗
  2. m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. Co-author DOI 10.1038/s41419-025-08049-2↗
  3. Changing Trends in the Global Disease Burden of Pancreatic Cancer from 1990 to 2030. Last author DOI 10.1007/s10620-024-08465-y↗
  4. Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101561↗
  5. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2022-329349↗
  6. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. Co-author DOI 10.1038/s41388-022-02306-w↗
  7. The m6A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathw… First author DOI 10.1186/s12943-022-01647-0↗
  8. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12935-021-01900-4↗
  9. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fimmu.2021.648917↗
  10. Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fonc.2021.643465↗
  11. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Co-author DOI 10.1186/s12943-019-1117-9↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 7 shared papers, 2021–2025 · strength 1.07
  2. Qingcai Meng · 7 shared papers, 2019–2025 · strength 0.99
  3. Chen Liang · 7 shared papers, 2019–2025 · strength 0.99
  4. Si Shi · 7 shared papers, 2019–2023 · strength 0.95
  5. Jie Hua · 6 shared papers, 2019–2023 · strength 0.77
  6. Rong Tang · 5 shared papers, 2021–2025 · strength 0.75
  7. Wei Wang · 5 shared papers, 2021–2023 · strength 0.71
  8. Jin Xu · 5 shared papers, 2019–2022 · strength 0.61
  9. Zhen Tan · 3 shared papers, 2022–2025 · strength 0.53
  10. Bo Zhang · 3 shared papers, 2021–2023 · strength 0.43
  11. Haoyu An · 1 shared paper, 2024 · strength 0.36
  12. Ji-Hui Hao · 1 shared paper, 2026 · strength 0.26
  13. Zhe Li · 1 shared paper, 2026 · strength 0.26
  14. Heng Zhu · 1 shared paper, 2025 · strength 0.22
  15. Xu He · 1 shared paper, 2025 · strength 0.22
  16. Jianhui Yang · 1 shared paper, 2025 · strength 0.22
  17. Mingming Xiao · 1 shared paper, 2025 · strength 0.22
  18. Zeyin Rong · 1 shared paper, 2025 · strength 0.22
  19. Jin Xu · 1 shared paper, 2025 · strength 0.22
  20. Jin Xu · 1 shared paper, 2023 · strength 0.18
  21. Miaoyan Wei · 1 shared paper, 2023 · strength 0.18
  22. Jialin Li · 1 shared paper, 2023 · strength 0.18
  23. Hang Xu · 1 shared paper, 2023 · strength 0.18
  24. Yiyin Zhang · 1 shared paper, 2023 · strength 0.16
  25. Yi Zhang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.